The activity of monotherapy with Lenalidomide will be evaluated in patients with lymphoma of
the mucosa associated lymphoid tissue (MALT).
We will connect you to the doctor responsible for this trial and help you get more information.
Locations near you
Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Full eligibility criteria for NCT00923663
Ages eligible for Study
18 Years to 80 Years
Genders eligible for Study
Accepts Healthy Volunteers
Patients with histologically confirmed MALT lymphoma with measurable disease (stage I
With first or greater relapse after HP-eradication, radiation or chemotherapy in case of gastric lymphoma
Age > 18 years
Must be able to tolerate therapy, and have adequate cardiac, renal, and hepatic function, ECOG status of 0 - 2
Must be capable of understanding the purpose of the study and have given written informed consent
Lymphoma histology other than MALT lymphoma or MALT lymphoma with a diffuse large cell lymphoma ("high grade lymphoma") - component
Use of any investigational agent within 28 days prior to initiation of treatment with lenalidomide
History of malignancy other than squamous cell carcinoma, basal cell carcinoma of the skin or carcinoma in situ of the cervix within the last 5 years
Major surgery, other than diagnostic surgery, within the last 4 weeks
Evidence of CNS involvement
A history of uncontrolled seizures, central nervous system disorders or psychiatric disability judged by the investigator to be clinically significant and adversely affecting compliance to study drugs
Severe peripheral polyneuropathy
Clinically significant cardiac disease (e.g., congestive heart failure, symptomatic coronary artery disease and cardiac arrhythmias not well controlled with medication) or myocardial infarction within the last 6 months
Inadequate hematological status at baseline prior to study entry: Dependency on red blood cell and/or platelet transfusions, ANC (absolute neutrophil count (segmented + bands)) < 1.0 x 109/L
Patients with active opportunistic infections
Uncontrolled diabetes mellitus
Preexisting thromboembolic events at start of study
All locations for NCT00923663
Dept of Internal Medicine
Vienna, Austria, A-1090
Put me in touch!
View full eligibility
Tris trial is registered with FDA with number: NCT00923663. The sponsor of the trial is Medical University of Vienna and it is looking for 16 volunteers for the current phase.
Official trial title: Phase II Trial of Lenalidomide in Patients With Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT) Type
1What's a trial
4Get in touch
What's a trial
Not sure you're well informed about clinical trials? Learn more about their benefits, risks and other important details.
Enter your details like condition, age, gender and other preferences and we will show you a list of all relevant clinical trials.
Review the summary of the selected clinical trial and all the locations near you in order to see if it's of interest to you.
Get in touch
You've found an interesting trial? We'll need a bit more information about you so we can connect you to the doctor in charge.
Thank you for applying!
We'll contact you soon with more information.
FindMeCure is constantly improving its search. Take part in it and help millions by filling our patients' survey!